Sirnaomics to Unveil GalAhead™ Therapeutic Platform Updates at Industry Conferences
14 June 2023 | Wednesday | News
irnaomics Ltd. (the "Company"; stock code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced that the Company will present the latest developments on GalAhead™, a GalNAc-RNAi therapeutic platform, and its pipeline programs, at three international industry conferences taking place in June: the Precision in Drug Discovery & Preclinical Summit, RNA Therapeutics USA, and 19th Drug Discovery Nexus.
Image Source : Public Domain
The Company's first GalAhead™-based RNAi drug candidate, STP122G, has started a Phase I clinical trial in May 2023. The start of the trial indicates that Sirnaomics' proprietary GalNAc RNAi platform technology, GalAhead™, has the potential to help patients with high unmet needs in the areas of hematologic, cardiometabolic, immunologic and rare disorders.
Precision in Drug Discovery & Preclinical Summit Oral Presentation Details
- Presentation Title: A Novel Therapeutic GalNAc-RNAi Platform to Downregulate Single and Multiple Genes
- Presenter: Dmitry Samarsky, PhD, Sirnaomics Chief Technology Officer
- Time/Date: 2:55 pm-3:20 pm ET on Tuesday, Jun 13, 2023
- Location: Revere Hotel, Boston, USA
RNA Therapeutics USA Oral Presentation Details
- Presentation Title: GalAhead™: a novel therapeutic GalNAc-RNAi platform to downregulate single and multiple Genes
- Presenter: Jim Weterings, PhD, Sirnaomics Senior Director of Technology Innovation
- Time/Date: 3:10 pm-3:50 pm ET on Thursday, June 15, 2023
- Location: Horton Grand Hotel; San Diego, USA
19th Drug Discovery Nexus Oral Presentation Details
- Presentation Title: GalAhead™: A Novel Therapeutic GalNAc-RNAi Platform to Downregulate Single and Multiple Genes
- Presenter: Jack Wei, PhD, Sirnaomics Senior Director of Drug Discovery
- Time/Date: 3:15 pm -3:40 pm ET on Friday, June 16, 2023
- Location: Holiday Inn Express – Arena Towers; Amsterdam, Netherlands
Most Read
- Lack of Regular Screening Fuels Rise in Late-Stage Breast Cancer in Hong Kong, New Report Reveals
- BIOCHINA 2025: Connecting Global Innovators with China's Leading Biotech Firms
- Leon Wyszkowski, President of Analytical Services, Discusses Thermo Fisher's Strategic Move: Expanding Bioanalytical Capabilities in Europe with New Sweden Lab
- The Role of Policy and Public Health Initiatives in Addressing Women's Cancer Care in Asia
- Redefining Patient Safety in the Age of Healthtech
Bio Jobs
- Avance Clinical Appoints Jessica Han as Director of Asian Operations, Strengthening Commitment to the Asian Market
- Bristol Myers Squibb Employees Cycle Coast-to-Coast to Raise $1 Million for Cancer Research
- Pfizer Australia Commits $150M to Upgrade Melbourne Facility, Bolstering Global Fight Against Antimicrobial Resistance
- SMi Systems Appoints Dr. Stefan Hamill as Vice President of Strategy to Drive Commercialisation and Growth
- Thermo Fisher Scientific Appoints William Hung as Senior Director and General Manager for Taiwan
- Cytiva Appoints Industry Veteran Pierre-Alain Ruffieux as Chief Operating Officer
News
Editor Picks
